• Mashup Score: 0

    Prioritizing patient values—who/what matters most—is central to palliative care and critical to treatment decision making. Yet which factors are most important to family caregivers in these decisions remains understudied. Using data from a U.S. national survey of cancer caregivers (N = 1661), we examined differences in factors considered very important by caregivers when partnering with patients in cancer treatment decision making by cancer stage and caregiver sociodemographics. Fifteen factors were rated on a 4-point Likert-scale from ‘very unimportant’ to ‘very important.’ Descriptive statistics were used to characterize caregiver factors and tabulate proportions of importance for each. Generalized linear mixed effect modeling was used to examine the importance of factors by cancer stage, and chi-square analyses were performed to determine associations between caregiver sociodemographics and the five most commonly endorsed factors: quality of life (69%), physical well-being (68%), le

    Tweet Tweets with this article
    • What Is Most Important to Family #Caregivers When Helping Patients Make Treatment-Related Decisions: Findings from a National Survey. https://t.co/qS8SwFoBJk @UAB_ICOS @NickOdomPhD_RN @TamrynGray #Caregiving #PallOnc #GeriOnc #CancerResearch https://t.co/EQvq8s4mMq

  • Mashup Score: 1

    ASCO President Lynn Schuchter, MD, FASCO, has made access to palliative and supportive care among patients with cancer a central focus of her presidential term. Although not all cancer clinicians can be palliative care specialists, because palliative and supportive care are so essential to every patient’s treatment plan, ASCO is hosting a complimentary webinar, Making Palliative Care a Part of Your Oncology Practice, to provide clinicians with resources to integrate palliative and supportive care into

    Tweet Tweets with this article
    • .@ASCO Launches New Webinar: Making Palliative Care a Part of Your Oncology Practice https://t.co/76gahuTshF #oncology #pallonc

  • Mashup Score: 2

    The 2023 ASCO President, Lynn Schuchter, MD, FASCO, has made providing palliative and supportive care to all patients with cancer a central focus in her presidential theme, “The Art and Science of

    Tweet Tweets with this article
    • In recognition of World Hospice & Palliative Care Day, we’re pleased to present a new webinar that outlines practical tools for integrating palliative & supportive care into your oncology practice. Watch: https://t.co/Vp7oJUa5Jd @jrgralow @ASCOPres #WHPCDay23 #pallonc #supponc https://t.co/OZLOky7crc

  • Mashup Score: 2

    PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability to understand patient toxicity burden. We analyze the relationship between the grades of AEs experienced with patient side-effect bother and treatment discontinuation. METHODS We analyzed a phase III Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial with comprehensive AE data. The Likert response Functional Assessment of Cancer Therapy-GP5 item, “I am bothered by side effects of treatment” was used to define side-effect bother. Bayesian mixed models were used to assess the impact of G1 and G2 AE counts on patient side-effect bother and treatment discontinuation. AEs were further analyzed on the basis of symptomatology (symptomatic or asymptomatic). The results are given as odds ratios (ORs) and

    Tweet Tweets with this article
    • Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. https://t.co/TcXX39ma6u @eaonc @ASCO @JCO_ASCO @JCOOP_ASCO #PallOnc #GeriOnc #SuppOnc #CancerResearch https://t.co/klbvLU8Q0N